Involvement of OX40 ligand+ mast cells in chronic GVHD after allogeneic hematopoietic stem cell transplantation [1]

Bone Marrow Transplantation

Volumn 39, Issue 6, 2007, Pages 373-375

  Kotani, A ^a   Hori, T ^a   Fujita, T ^a   Kambe, N ^a   Matsumura, Y ^a   Ishikawa, T ^a   Miyachi, Y ^a   Nagai, K ^b   Tanaka, Y ^c   Uchiyama, T ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; TOLONIUM CHLORIDE; TUMOR NECROSIS FACTOR RECEPTOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DERMIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LETTER; LYMPHOCYTE PROLIFERATION; MALE; MAST CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKIN BLOOD VESSEL; SKIN DISEASE; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIGENS, DIFFERENTIATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MAST CELLS; MIDDLE AGED; OX40 LIGAND; SKIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 33947135955     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705587     Document Type: Letter

References (10)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
2. Hori T. Roles of OX40 in the pathogenesis and the control of diseases. Int J Hematol 2006; 83: 17-22.
3. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood 1997; 89: 4652-4658.
4. +) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3162-3164.
5. Matsumura Y, Hori T, Nishigori C, Shirogane K, Toda KI, Uchiyama T et al. Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin. Arch Dermatol Res 2003; 294: 563-566.
6. Canninga-van Dijk MR, Sanders CJ, Verdonck LF, Fijnheer R, van den Tweel JG. Differential diagnosis of skin lesions after allogeneic haematopoietic stem cell transplantation. Histopathology 2003; 42: 313-330.
7. Kashiwakura J, Yokoi H, Saito H, Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: Comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 2004; 173: 5247-5257.
8. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005; 6: 135-142.
9. Henz BM, Maurer M, Lippert U, Worm M, Babina M. Mast cells as initiators of immunity and host defense. Exp Dermatol 2001; 10: 1-10.
10. Zweifel M, Hirsiger H, Matozan K, Welle M, Schaffner T, Mohacsi P. Mast cells in ongoing acute rejection: Increase in number and expression of a different phenotype in rat heart transplants. Transplantation 2002; 73: 1707-1716.